Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Use of Cannabidiol in the Treatment of Epilepsy: Efficacy and Security in Clinical Trials
Serena Silvestro, Santa Mammana, Eugenio Cavalli, et al.
Molecules (2019) Vol. 24, Iss. 8, pp. 1459-1459
Open Access | Times Cited: 219

Showing 1-25 of 219 citing articles:

The antimicrobial potential of cannabidiol
Mark A. T. Blaskovich, Angela M. Kavanagh, Alysha G. Elliott, et al.
Communications Biology (2021) Vol. 4, Iss. 1
Open Access | Times Cited: 222
The Endocannabinoid System: A Potential Target for the Treatment of Various Diseases
Henry Lowe, Ngeh J. Toyang, Blair Steele, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 17, pp. 9472-9472
Open Access | Times Cited: 202
A narrative review of molecular mechanism and therapeutic effect of cannabidiol (CBD)
Jiangling Peng, Mingjie Fan, Chelsea An, et al.
Basic & Clinical Pharmacology & Toxicology (2022) Vol. 130, Iss. 4, pp. 439-456
Open Access | Times Cited: 180
Reasons for cannabidiol use: a cross-sectional study of CBD users, focusing on self-perceived stress, anxiety, and sleep problems
Julie Moltke, Chandni Hindocha
Journal of Cannabis Research (2021) Vol. 3, Iss. 1
Open Access | Times Cited: 110
Cannabis: a multifaceted plant with endless potentials
Eric Fordjour, Charles F. Manful, Albert Adu Sey, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 46
Mitochondrial dysfunction in chronic neuroinflammatory diseases (Review)
Pei Qin, Ye Sun, Liya Li
International Journal of Molecular Medicine (2024) Vol. 53, Iss. 5
Open Access | Times Cited: 16
Cannabidiol prevents LPS‐induced microglial inflammation by inhibiting ROS/NF‐κB‐dependent signaling and glucose consumption
Maurício dos Santos Pereira, Franscisco S. Guimarães, Elaine Aparecida Del Bel, et al.
Glia (2019) Vol. 68, Iss. 3, pp. 561-573
Closed Access | Times Cited: 132
Targeting Endocannabinoid Signaling: FAAH and MAG Lipase Inhibitors
Noëlle van Egmond, Verena M. Straub, Mario van der Stelt
The Annual Review of Pharmacology and Toxicology (2020) Vol. 61, Iss. 1, pp. 441-463
Open Access | Times Cited: 81
Effects of Chronic Cannabidiol Treatment in the Rat Chronic Unpredictable Mild Stress Model of Depression
Zsolt Gáll, Szidónia Farkas, Ákos Albert, et al.
Biomolecules (2020) Vol. 10, Iss. 5, pp. 801-801
Open Access | Times Cited: 80
Phytocannabinoids: Useful Drugs for the Treatment of Obesity? Special Focus on Cannabidiol
Patrycja Bielawiec, Ewa Harasim‐Symbor, Adrian Chabowski
Frontiers in Endocrinology (2020) Vol. 11
Open Access | Times Cited: 75
The (Poly)Pharmacology of Cannabidiol in Neurological and Neuropsychiatric Disorders: Molecular Mechanisms and Targets
Rosa Maria Vitale, Fabio Arturo Iannotti, Pietro Amodeo
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 9, pp. 4876-4876
Open Access | Times Cited: 63
Cannabidiol and Cannabigerol Exert Antimicrobial Activity without Compromising Skin Microbiota
Mariana Veiga, Manuela Amorim, Inês Pinto-Ribeiro, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 3, pp. 2389-2389
Open Access | Times Cited: 31
Therapeutic applicability of cannabidiol and other phytocannabinoids in epilepsy, multiple sclerosis and Parkinson's disease and in comorbidity with psychiatric disorders
Maria de Fátima dos Santos Sampaio, Yara Bezerra de Paiva, Tuane Bazanella Sampaio, et al.
Basic & Clinical Pharmacology & Toxicology (2024) Vol. 134, Iss. 5, pp. 574-601
Open Access | Times Cited: 12
Cannabidiol Drugs Clinical Trial Outcomes and Adverse Effects
Christopher S. Pauli, Matthieu Conroy, Brian D. Vanden Heuvel, et al.
Frontiers in Pharmacology (2020) Vol. 11
Open Access | Times Cited: 68
Cannabinoids for People with ASD: A Systematic Review of Published and Ongoing Studies
Laura Fusar‐Poli, Vito Cavone, Silvia Tinacci, et al.
Brain Sciences (2020) Vol. 10, Iss. 9, pp. 572-572
Open Access | Times Cited: 66
Oxidative Stress, a Crossroad Between Rare Diseases and Neurodegeneration
Carmen Espinós, Máximo Ibo Galindo, María Adelaida García-Gimeno, et al.
Antioxidants (2020) Vol. 9, Iss. 4, pp. 313-313
Open Access | Times Cited: 59
Cannabidiol in Neurological and Neoplastic Diseases: Latest Developments on the Molecular Mechanism of Action
Marcin Ożarowski, Tomasz M. Karpiński, Aleksandra Zielińska, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 9, pp. 4294-4294
Open Access | Times Cited: 54
Chinese Herbal Medicine for Treating Epilepsy
Chia-Hui Lin, Ching‐Liang Hsieh
Frontiers in Neuroscience (2021) Vol. 15
Open Access | Times Cited: 44
Cannabidiol protects against Alzheimer's disease in C. elegans via ROS scavenging activity of its phenolic hydroxyl groups
Yue Zhang, Hongyuan Li, Sha Jin, et al.
European Journal of Pharmacology (2022) Vol. 919, pp. 174829-174829
Closed Access | Times Cited: 37
Neuroprotection of Cannabidiol, Its Synthetic Derivatives and Combination Preparations against Microglia-Mediated Neuroinflammation in Neurological Disorders
Muhammad Yousaf, Dennis Chang, Yang Liu, et al.
Molecules (2022) Vol. 27, Iss. 15, pp. 4961-4961
Open Access | Times Cited: 34
Cannabidiol for the treatment of autism spectrum disorder: hope or hype?
João Francisco Cordeiro Pedrazzi, Frederico Rogério Ferreira, Danyelle Silva-Amaral, et al.
Psychopharmacology (2022) Vol. 239, Iss. 9, pp. 2713-2734
Closed Access | Times Cited: 31
Emerging Therapeutic Potential of Cannabidiol (CBD) in Neurological Disorders: A Comprehensive Review
Kuldeep Singh, Bharat Bhushan, Dilip Kumar Chanchal, et al.
Behavioural Neurology (2023) Vol. 2023, pp. 1-17
Open Access | Times Cited: 19
Beyond Pain Relief: A Review on Cannabidiol Potential in Medical Therapies
Mariana Veiga, João Azevedo‐Silva, João Carlos Fernandes
Pharmaceuticals (2023) Vol. 16, Iss. 2, pp. 155-155
Open Access | Times Cited: 18
Orexin receptor antagonists in the pathophysiology and treatment of sleep disorders and epilepsy
Mohammad Sheibani, Maryam Shayan, Mina Khalilzadeh, et al.
Neuropeptides (2023) Vol. 99, pp. 102335-102335
Closed Access | Times Cited: 18
The Use of Compounds Derived from Cannabis sativa in the Treatment of Epilepsy, Painful Conditions, and Neuropsychiatric and Neurodegenerative Disorders
Anna Stasiłowicz-Krzemień, Wiktoria Nogalska, Zofia Maszewska, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 11, pp. 5749-5749
Open Access | Times Cited: 6
Page 1 - Next Page

Scroll to top